Journal Publications

Export 124 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
2011
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Barber T, Geretti A, Anderson J, Schwenk A, Phillips A, Bansi L, Gilson R, Hill T, Walsh J, Fisher M et al. Antivir Ther, 2011, Volume 16, Issue 6, p.805-14, (2011)
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. Cozzi-Lepri A, Prosperi M, Kjær J, Dunn D, Paredes R, Sabin C, Lundgren J, Phillips A and Pillay D. PLoS One, 2011, Volume 6, Issue 11, p.e25665, (2011)
2010
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. Fox J, Castro H, Kaye S, McClure M, Weber J and Fidler S. AIDS, 2010 Sep 24, Volume 24, Issue 15, p.2397-401, (2010)
Data linkage reduces loss to follow-up in an observational HIV cohort study. Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R et al. J Clin Epidemiol, 2010 Oct, Volume 63, Issue 10, p.1101-9, (2010)
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. Mackie N, Phillips A, Kaye S, Booth C and Geretti A. J Infect Dis, 2010 May 01, Volume 201, Issue 9, p.1303-7, (2010)
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. . Clin Infect Dis, 2010 May 01, Volume 50, Issue 9, p.1275-85, (2010)
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. Sabin C, Schwenk A, Johnson M, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K et al. AIDS, 2010 Mar 13, Volume 24, Issue 5, p.723-7, (2010)
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A et al. Arch Intern Med, 2010 Mar 08, Volume 170, Issue 5, p.410-9, (2010)
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lodwick R, Sabin C, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S et al. Lancet, 2010 Jul 31, Volume 376, Issue 9738, p.340-5, (2010)
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti A and Dunn D. AIDS, 2010 Jul 31, Volume 24, Issue 12, p.1917-22, (2010)
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Ray M, Logan R, Sterne J, Hernández-Díaz S, Robins J, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D et al. AIDS, 2010 Jan 02, Volume 24, Issue 1, p.123-37, (2010)
Factors influencing lopinavir and atazanavir plasma concentration. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B et al. J Antimicrob Chemother, 2010 Jan, Volume 65, Issue 1, p.129-37, (2010)
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. Gilson R, Man S, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C et al. HIV Med, 2010 Feb, Volume 11, Issue 2, p.152-60, (2010)
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M et al. J Viral Hepat, 2010 Aug, Volume 17, Issue 8, p.569-77, (2010)
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M et al. HIV Med, 2010 Aug, Volume 11, Issue 7, p.432-8, (2010)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 2, p.203-11, (2010)
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Chilton D, Castro H, Lattimore S, Harrison L, Fearnhill E, Delpech V, Rice B, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 7, p.985-91, (2010)
2009
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Murillo A, Mocroft A, Bonnet F, Clifford G, Touloumi G et al. AIDS, 2009 Sep 24, Volume 23, Issue 15, p.2029-37, (2009)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J et al. J Infect Dis, 2009 Sep 01, Volume 200, Issue 5, p.710-4, (2009)
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? Grant A, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2507-15, (2009)
Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Bansi L, Hughes A, Bhagani S, Mackie N, Leen C, Levy J, Edwards S, Connolly J, Holt S, Hendry B et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2517-21, (2009)
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M et al. J Acquir Immune Defic Syndr, 2009 Nov 01, Volume 52, Issue 3, p.391-6, (2009)
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Geretti A, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D and Dunn D. Clin Infect Dis, 2009 May 01, Volume 48, Issue 9, p.1296-305, (2009)
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P et al. Haematologica, 2009 Jun, Volume 94, Issue 6, p.875-80, (2009)